Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Immunosuppressive myeloid cells induce mesenchymal-like breast cancer stem cells by a membrane-bound TGF-β1-dependent mechanism.

Cell reports·2026

Same author

Blinatumomab bypasses CD28 blockade to sustain T-cell cytotoxicity and improve survival in a xenograft B-ALL model.

Journal for immunotherapy of cancer·2026

Same author

A Performance-Based Rubric for Generative AI use in Medical Students' Research Tasks: Development and Initial Psychometric Evaluation.

Journal of medical education and curricular development·2026

Same author

Post-Transplant Bendamustine as a Platform for Immune Modulation After Allogeneic Hematopoietic Cell Transplantation.

European journal of haematology·2026

Same author

TIGIT Blockade Potentiates the Anti-Leukemic Activity of Exercise-Mobilized Donor Lymphocytes and Expanded γδ T-Cells.

Cancers·2026

Same author

Exercise-mobilized lymphocytes enhance antibody-based immunotherapy in multiple myeloma through CD16<sup>+</sup> NK cell-mediated cytotoxicity.

Journal of translational medicine·2026

Same journal

Anti-TIGIT therapies in digestive cancers: from immune evasion to precision immunotherapy.

Immunotherapy·2026

Same journal

CAR cellular therapies for acute myeloid leukemia: current landscape and future directions.

Immunotherapy·2026

Same journal

Recent advances in bispecific natural killer cell engagers for cancer immunotherapy.

Immunotherapy·2026

Same journal

Exploring global research trends in sublingual immunotherapy of allergic rhinitis: a comprehensive bibliometric analysis.

Immunotherapy·2026

Same journal

Autoimmune encephalitis and axonal polyradiculoneuropathy following therapy with adalimumab and secukinumab: a case report and literature review.

Immunotherapy·2026

Same journal

Time-dependent prognostic impact of distant metastatic sites in small cell lung cancer: a comparative analysis of pre- and post-immunotherapy eras.

Immunotherapy·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Personalized dendritic cell-based tumor immunotherapy.

Nona Janikashvili¹, Nicolas Larmonier, Emmanuel Katsanis

¹Department of Pediatrics, Steele Children's Research Center, Arizona 85724, USA.

|February 18, 2010

Summary

This summary is machine-generated.

Personalized dendritic cell (DC) vaccines offer a promising approach to cancer immunotherapy by presenting a full range of tumor antigens. However, improving their clinical efficacy remains a key challenge for future cancer treatment strategies.

Keywords:

anticancer immune response chaperone protein dendritic cell idiotype personalized tumor vaccine tumor lysate

More Related Videos

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Experiment Videos

Last Updated: Jun 16, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Area of Science:

Immunology
Oncology
Vaccinology

Background:

Dendritic cells (DCs) are crucial for initiating immune responses and have been explored for anticancer vaccines.
While DC-based immunotherapy is safe and induces tumor-specific immunity, clinical responses in cancer patients are limited.

Purpose of the Study:

To review personalized DC-based anticancer vaccines.
To discuss their potential to present a comprehensive array of autologous tumor antigens.
To explore their implementation in cancer therapeutic strategies, limitations, and future challenges.

Main Methods:

Review of current literature on DC-based anticancer vaccines.
Analysis of personalized DC vaccine strategies.
Discussion of clinical implementation and challenges.

Main Results:

Personalized DC vaccines theoretically present a complete repertoire of tumor antigens.
Current DC vaccine efficacy in cancer patients is limited, necessitating further research.

Conclusions:

Personalized DC vaccines hold significant theoretical potential for cancer immunotherapy.
Overcoming limitations and addressing future challenges are critical for enhancing the effectiveness of DC-based cancer vaccines.